REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL	Application No.: Filing Date:	10/024,858 December 18, 2001
Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995. See The American Inventors Protection Act of 1999 (AIPA).	First Named Inventor: Group Art Unit: Examiner:	· · · · · · · · · · · · · · · · · · ·
	Attorney Docket No.:	P31220X2C2
CERTIFICATION OF FACSIMILE TRANSMISSION		FAX RECEIVED
I hereby certify that this paper is being facsimile transmitted to the		
U.S. Patent and Trademark Office on the date shown below.		NOV 2 2 2005
Type Name of Person faxing this document Thurs November 22, 2005		OFFICE OF PETITIONS
Signature	Date	

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

NOTE: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Final Rule, 65 Fed. Reg. 50092 (Aug 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20,2000) 1233 Off. Gaz Pat. Office 47 (April 11, 2000), which established RCE practice.

1. Submission required under 37 C.F.R. § 1.114	
a. Previously submitted	
i. Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on	
(Any unentered amendment(s) referred to above will be entered)	į
ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed on	
iii. Other	· ·
b. Enclosed	
i. E Amendment/Reply 3 pages	
ii. ☐ Affadavit(s)/Declaration(s) pages	
iii. 🗵 Information Disclosure Statement (IDS) 1 page	•
iv. ☐ Form PTO 1449 1 pg. & 3 References	,
v. Return Receipt Postcard (MPEP 503) (specifically itemized)	
vi. Other	
2. Miscellancous	1
a. Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.1	
for a period of months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.	103 (c)
b. \square Other	1.17(I) required)
3. FEES The RCB fee under 37 C.F.R. § 1.117(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.	
The state of the s	
a. Enteropy authorized to charge the following fees or credit any overpayments. Deposit Account No. 19-2570.	, to
Constituted in 19-2570.	
General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions of time relating to this application.	s for extensions
57 CFR 7.130(a)(3))	
1. Exces fee required under 37 C.F.R. § 1.17(e). \$790.00	485
 ii. □ () Month Extension of time fee (37 C.F.R. §§ 1.136 and 1.17) iii. □ Additional Fees 	10024858
m. D Additional rees	=
	9
iv. Total Fee to be charged to Deposit Account 19-2570 \$790.00	192570
	15
CORRESPONDENCE ADDRESS RESPECTEULLY SUBA	018 DA
CORRESPONDENCE ADDRESS RESPECTFULLY SUBM	MITTED, 8
Address GLAXOSMITHKLINE	MITTED, 8
Corporate Intellectual Property – UW2220 Signature	Manna
P.O. Box 1539	W. S.
King of Prussia, PA 19406-0939	AKEI
Telephone (610) 270-5023 Facsimile (610) 270-5090 Registration No. 33,870	& g
\wjd\paroxetine\P312220 Paxil CR\RCE-3.doc	<u> </u>